News

With every 10-year increase in patient age, the risk of the patients needing concomitant administration of steroid eye drops decreased by half, according to investigators.

A team of researchers with the West Virginia School of Medicine are studying how a benign virus can make new treatments for eye diseases possible.

A team of researchers from Thomas Jefferson University have found that immune cells could be doing much more than first thought in protecting our eyes.

A virtual, risk-based approach to preoperative medical evaluations for cataract surgery may be associated with safe and efficient outcomes, according to study investigators.

Robert H. Osher, MD, shows the merits of drug delivery via capsular bag after cataract surgery.

The cell-by-cell atlas will help in the study of eye disorders and development of cell therapy to replace damaged eye tissue.

According to the company, a suprachoroidal injection of CLS-AX 0.1 mg dose was well-tolerated in cohort 2 with no treatment related adverse events, while the consistent safety profile observed in in cohorts 1 and 2 supports advancement to cohort 3.

Analysis finds acceptable outcomes can be expected when pterygium surgery is performed by a supervised ophthalmology resident.

Researchers found there was, on average, a 17% improvement in participants’ color contrast vision when exposed to three minutes of deep red light in the morning.

Ahmad Aref, MD, and Paul Singh, MD, offer a recap of their EyeCon 2021 presentation.

Ophthalmologists continue to rise to the challenge amid myriad hurdles.

Real-world evidence is growing in importance as a source of information that can help support clinical decision-making when evaluated properly.

Hear what Sumayya Ahmad, MD, and Jai G. Parekh, MD, MBA, have to say about current concepts for the management and treatment of dry eye.

The company anticipates that the Sirius and Celeste studies will further validate QR-421a’s ability to stabilize vision loss in people with USH2A mediated retinitis pigmentosa and Usher syndrome.

The US Orphan Drug Designation would provide seven-year market exclusivity if Visomitin was approved for use in LHON.

Researchers at the University of Virginia School of Medicine have made a discovery linking lupus, a potentially debilitating autoimmune disorder, and macular degeneration, a leading cause of blindness.

According to the organization, the goal is to highlight and address the diverse and critical vision and eye health needs of children and to improve outcomes through advocacy, public health, education, and awareness.

Several research giants will team up to beat rare diseases that are currently using gene therapy.

The difference in visual acuities based on CST fluctuations in these patients with diabetic macular edema remained significant.

An elevated risk may be associated with the cataract type, case complexity, and history of diabetic macular edema or proliferative diabetic retinopathy.

SD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.

According to the company, OK-101 displays both anti-inflammatory and ocular pain-reducing potential.

For surgeons, the decision goes beyond clarifying a patient’s vision.

Although graft rejection has not been associated with vaccinations, concern remains.

According to Lisa Nijm, MD, JD, patients can benefit from short-term, on-label treatment with a novel loteprednol formulation

Investigators say renal function could be used as a possible predictor for poor treatment response in certain patients with diabetic macular edema.

I-MED Pharma Inc., a Canadian-based firm, announced this week the expansion of its strategic partnership with ESW Vision in France to be their exclusive distributor in the United States.

TearLab Corp. announced that Adam Szaronos has been appointed president and CEO by the company's Board of Directors, effective immediately.